Global Age-related Macular Degeneration Market

Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Drug Type(Aflibercept, Ranibizumab, and Others), By Disease Type(Wet Age-Related Macular Degeneration (AMD) and Dry Age-Related Macular Degeneration (AMD)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35I2349 | Region: Global | Published Date: October, 2024
Pages: 193 | Tables: 88 | Figures: 71

Age-related Macular Degeneration Market News

  • In September 2024, The FDA has just approved a new AMD therapy called Beovu by Novartis. As such, the dosing regime is less frequent than other currently available therapies for AMD leading to an improved patient adherence and effective vision preservation. In so doing, periodic reminders of Novartis's aims to advance care for AMD patients are provided with better results.
  • In July 2024, Lenchite, the pharmaceutical company Regeneron unveiled good Phase III results for Eylea that is used together with other drugs to treat AMD. The results show better sight conditions and longer intervals between treatments. The data shows that vision outcomes are better, and treatment intervals can be increased. This development highlights Regeneron's ongoing efforts to enhance treatment efficacy and provide more flexible options for managing wet AMD.
  • In August 2024, Apellis Pharmaceuticals launched Empaveli, a novel treatment for dry AMD. This breakthrough therapy targets complement pathway inhibition, addressing a significant unmet need in dry AMD management. The launch marks a significant milestone in Apellis’s strategy to provide innovative solutions for chronic retinal diseases.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Age-related Macular Degeneration Market size was valued at USD 10.52 Billion in 2022 poised to grow from USD 11.24 Billion in 2023 to USD 19.18 Billion by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

The competitive global age-related macular degeneration market denotes that a host of various pharmaceutical companies struggle to capture market share with their new therapies. Novartis’ Lucentis is one of the key anti-VEGF drugs while Eylea, developed by Regeneron Pharmaceuticals, stands out. To mention but a few Roche’s Avastin is part of key players in this field. They work hard developing advanced treatment modalities meant at ensuring better patient outcomes and filling any existing gap in terms of successful therapies. Thereby competition enhances ongoing innovations, which consequently leads to more effective treatments being available for AMD patients globally. 'Novartis (Switzerland)', 'Regeneron Pharmaceuticals (USA)', 'Roche (Switzerland)', 'Bayer (Germany)', 'Allergan (USA)', 'Pfizer (USA)', 'AbbVie (USA)', 'Apellis Pharmaceuticals (USA)', 'Stealth BioTherapeutics (USA)', 'Iveric Bio (USA)', 'Kymab (UK)', 'Ophthotech Corporation (USA)', 'Zymeworks (Canada)', 'Galderma (Switzerland)', 'EyePoint Pharmaceuticals (USA)'

Increased elderly population being susceptible to AMD is driving the global age-related macular degeneration market. The longer people live, the more they are exposed to its risk which leads in turn to requests for AMD therapies and treatments so as to manage and stop sight loss.

Emergence of Long-Acting Therapies: In the AMD market there is an increasing trend towards long-action therapies like anti-VEGF treatments of extended duration. These innovations help in reducing the number of times patients need to be injected, hence improving their compliance and results; thus, fueling growth within the market that has had its challenges with earlier treatments.

North America is ahead in the global age-related macular degeneration market as its healthcare system is advanced, it has a high prevalence rate of AMD and there are significant investments in research. In addition, the region enjoys established regulatory pathways which enable faster access to innovative treatments. Moreover, there are strong awareness programs and high health care expenditures that support the wide use of advanced therapies. The presence of leading pharmaceutical companies and clinical trial hubs in North America further supports its dominance. The growing aging population and increasing incidence of AMD in this region drive continuous demand for effective treatment solutions, reinforcing North America's market leadership.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Age-related Macular Degeneration Market

Report ID: SQMIG35I2349

$5,300
BUY NOW GET FREE SAMPLE